Published in Neuro Oncol on September 09, 2015
Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med (2011) 45.46
MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. Lancet Oncol (2013) 4.26
Wnt signalling required for expansion of neural crest and CNS progenitors. Nature (1997) 3.11
Multiple congenital melanocytic nevi and neurocutaneous melanosis are caused by postzygotic mutations in codon 61 of NRAS. J Invest Dermatol (2013) 2.74
Control of neural crest cell fate by the Wnt signalling pathway. Nature (1998) 2.71
Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma. Nat Med (2012) 2.26
Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo. Proc Natl Acad Sci U S A (2013) 1.88
Cancer stem cells in breast: current opinion and future challenges. Pathobiology (2008) 1.77
A comparison of ARMS and DNA sequencing for mutation analysis in clinical biopsy samples. J Exp Clin Cancer Res (2010) 1.68
Clonogenic cell subpopulations maintain congenital melanocytic nevi. J Invest Dermatol (2014) 1.42
Human melanocytes cultured from nevi and melanomas. J Invest Dermatol (1986) 1.36
Expansion of CD133(+) colon cancer cultures retaining stem cell properties to enable cancer stem cell target discovery. Br J Cancer (2010) 1.35
Spectrum of central nervous system abnormalities in neurocutaneous melanocytosis. Dev Med Child Neurol (2012) 1.24
Selective RAF inhibitor impairs ERK1/2 phosphorylation and growth in mutant NRAS, vemurafenib-resistant melanoma cells. Pigment Cell Melanoma Res (2013) 1.13
New recommendations for the categorization of cutaneous features of congenital melanocytic nevi. J Am Acad Dermatol (2012) 1.07
Oncogenic NRAS has multiple effects on the malignant phenotype of human melanoma cells cultured in vitro. Int J Cancer (2009) 1.05
Druggable targets in pediatric neurocutaneous melanocytosis: Molecular and drug sensitivity studies in xenograft and ex vivo tumor cell culture to identify agents for therapy. Neuro Oncol (2014) 1.02
BRAF mutations are also associated with neurocutaneous melanocytosis and large/giant congenital melanocytic nevi. Pediatr Dev Pathol (2014) 1.02
Targeting NRAS in melanoma. Cancer J (2012) 1.00
MEK targeting in N-RAS mutated metastatic melanoma. Mol Cancer (2014) 0.98
Growth regulation of cultured human nevus cells. J Invest Dermatol (1993) 0.92
Cellular origin and developmental mechanisms during the formation of skin melanocytes. Exp Cell Res (2010) 0.91
Nevomelanocytic proliferations in the central nervous system of children. Cancer (1993) 0.86
In vitro assessment of antitumor activities of the PI3K/mTOR inhibitor GSK2126458. Cancer Cell Int (2014) 0.84
Establishment and characterization of a malignant melanoma cell line (YP-MEL) derived from a patient with neurocutaneous melanosis. Pathol Res Pract (1994) 0.83
Making a mountain out of a molehill: NRAS, mosaicism, and large congenital nevi. J Invest Dermatol (2013) 0.83